Drugs / NaQuinate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04036617 | Jun → Dec 2019 | osteoporosis | Haoma Medica Limited | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2022-09-16 | Haoma Medica Limited | Results Haoma Medica Announces Late-Breaking Science Results for Naquinate, as a New Way to Support Bone Health and Healthy Aging, at the ASBMR 2022 Annual Meeting haomamedica.com ↗
In the data presented today using primary human femoral osteoblasts, Naquinate increased osteoblast proliferation after 3 days compared to control cultures. |
| 2020-11-26 | Haoma Medica Limited | Results Haoma Medica Completes First-in-Human Trial for NaQuinate, a Novel Treatment in Development for Osteoporosis haomamedica.com ↗
There were no significant safety or tolerability concerns up to the highest doses tested which underlines our expectation that NaQuinate is safe and well tolerated, |
| 2020-09-11 | Haoma Medica Limited | Results Haoma Medica Announces Plenary Presentation for NaQuinate, a Potential Novel Treatment for Osteoporosis, at ASBMR 2020 Annual Meeting haomamedica.com ↗
Previous studies have shown NaQuinate, a naphthoquinone carboxylic acid, to protect against reduction in bone quality and quantity occurring in response to ovariectomy in rat and mouse models. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-09-16 | Haoma Medica Limited | Haoma Medica Announces Late-Breaking Science Results for Naquinate, as a New Way to Support Bone Health and Healthy Aging, at the ASBMR 2022 Annual Meeting haomamedica.com ↗ |
| 2020-11-26 | Haoma Medica Limited | Haoma Medica Completes First-in-Human Trial for NaQuinate, a Novel Treatment in Development for Osteoporosis haomamedica.com ↗ |
| 2020-09-11 | Haoma Medica Limited | Haoma Medica Announces Plenary Presentation for NaQuinate, a Potential Novel Treatment for Osteoporosis, at ASBMR 2020 Annual Meeting haomamedica.com ↗ |
| 2020-09-10 | Haoma Medica Limited | Haoma Medica to Present Scientific Data on NaQuinate, a Potential New Treatment for Osteoporosis, at the Upcoming ASBMR 2020 Annual Meeting haomamedica.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NaQuinate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04036617 ↗ |
| Route | Oral | “single ascending oral (PO) doses and multiple ascending PO doses” NCT04036617 ↗ |